About neurosense therapeutics ltd - NRSN
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
NRSN At a Glance
Neurosense Therapeutics Ltd.
11 HaMenofim Street
Herzliya, Tel Aviv 4672562
| Phone | 972-9-799-6183 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -10,210,000.00 | |
| Sector | Health Technology | Employees | 15 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
NRSN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 10.791 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.921 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.004 |
NRSN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -680,666.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NRSN Liquidity
| Current Ratio | 2.21 |
| Quick Ratio | 2.21 |
| Cash Ratio | 1.713 |
NRSN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -263.45 |
| Return on Equity | -2,880.113 |
| Return on Total Capital | -384.413 |
| Return on Invested Capital | -2,611.253 |
NRSN Capital Structure
| Total Debt to Total Equity | 2.826 |
| Total Debt to Total Capital | 2.748 |
| Total Debt to Total Assets | 1.596 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |